Click to see the full list

1.            Verdecchia P, Mazzotta G, Angeli F, Reboldi G. Above Which Blood Pressure Level Does the Risk of Atrial Fibrillation Increase? Hypertension. Jan 17 2012.

2.            Reboldi G, Gentile G, Manfreda VM, Angeli F, Verdecchia P. Tight blood pressure control in diabetes: evidence-based review of treatment targets in patients with diabetes. Curr Cardiol Rep. Feb 2012;14(1):89-96.

3.            Reboldi G, Gentile G, Angeli F, Ambrosio G, Mancia G, Verdecchia P. Blood pressure lowering in diabetic patients. J Hypertens. Feb 2012;30(2):438-439.

4.            Angeli F, Reboldi G, Verdecchia P. Finding a place for aliskiren in the wide spectrum of blood pressure lowering agents. Hypertens Res. Jan 2012;35(1):17-19.

5.            Verdecchia P, Angeli F, Gentile G, Mazzotta G, Reboldi G. Telmisartan for the reduction of cardiovascular morbidity and mortality. Expert Rev Clin Pharmacol. Mar 2011;4(2):151-161.

6.            Reboldi G, Gentile G, Angeli F, Verdecchia P. Pharmacokinetic, pharmacodynamic and clinical evaluation of aliskiren for hypertension treatment. Expert Opin Drug Metab Toxicol. Jan 2011;7(1):115-128.

7.            Reboldi G, Gentile G, Angeli F, Verdecchia P. Optimal therapy in hypertensive subjects with diabetes mellitus. Curr Atheroscler Rep. Apr 2011;13(2):176-185.

8.            Reboldi G, Gentile G, Angeli F, Ambrosio G, Mancia G, Verdecchia P. Effects of intensive blood pressure reduction on myocardial infarction and stroke in diabetes: a meta-analysis in 73,913 patients. J Hypertens. Jul 2011;29(7):1253-1269.

9.            Grossman E, Verdecchia P, Shamiss A, Angeli F, Reboldi G. Diuretic treatment of hypertension. Diabetes Care. May 2011;34 Suppl 2:S313-319.

10.          Degoma EM, Knowles JW, Angeli F, Budoff MJ, Rader DJ. The Evolution and Refinement of Traditional Risk Factors for Cardiovascular Disease. Cardiol Rev. Dec 16 2011.

11.          Angeli F, Reboldi G, Verdecchia P. More than a REASON to use arterial stiffness as risk marker and therapeutic target in hypertension. Hypertens Res. Apr 2011;34(4):445-447.

12.          Angeli F, Reboldi G, Verdecchia P. Modern treatment of patients at risk: still a HOPE for ACE inhibitors? Expert Opin Pharmacother. Apr 2011;12(6):839-843.

13.          Angeli F, Reboldi G, Verdecchia P. Good news for beta-blockers in perioperative medicine. Expert Opin Drug Saf. Jul 2011;10(4):491-498.

14.          Angeli F, Reboldi G, Verdecchia P. Lowering blood pressure with beta-blockers in peripheral artery disease: the importance of comorbidity. J Hypertens. Jul 2011;29(7):1298-1302.

15.          Angeli F, Angeli E, Reboldi G, Verdecchia P. Hypertensive disorders during pregnancy: clinical applicability of risk prediction models. J Hypertens. Dec 2011;29(12):2320-2323.

16.          Angeli F, Angeli E, Ambrosio G, et al. Neutrophil count and ambulatory pulse pressure as predictors of cardiovascular adverse events in postmenopausal women with hypertension. Am J Hypertens. May 2011;24(5):591-598.

17.          Angeli E, Verdecchia P, Narducci P, Angeli F. Additive value of standard ECG for the risk prediction of hypertensive disorders during pregnancy. Hypertens Res. Jun 2011;34(6):707-713.

18.          Verdecchia P, Gentile G, Angeli F, Mazzotta G, Mancia G, Reboldi G. Influence of blood pressure reduction on composite cardiovascular endpoints in clinical trials. J Hypertens. Jul 2010;28(7):1356-1365.

19.          Verdecchia P, Angeli F, Mazzotta G, Reboldi G. Is hydrochlorothiazide more effective on LVH in nonresponders to losartan than in those to atenolol? Am J Hypertens. Jul 2010;23(7):705.

20.          Verdecchia P, Angeli F, Mazzotta G, et al. Aliskiren versus ramipril in hypertension. Ther Adv Cardiovasc Dis. Jun 2010;4(3):193-200.

21.          Verdecchia P, Angeli F, Mazzotta G, Gentile G, Reboldi G. [Arterial hypertension: an update]. G Ital Cardiol (Rome). May 2010;11(5 Suppl 3):74S-77S.

22.          Verdecchia P, Angeli F, Mazzotta G, Ambrosio G, Reboldi G. Angiotensin receptor blockers in hypertension. New insights from Japan. Hypertens Res. May 2010;33(5):394-397.

23.          Verdecchia P, Angeli F, Mazzotta G, Ambrosio G, Reboldi G. Angiotensin converting enzyme inhibitors and angiotensin receptor blockers in the treatment of hypertension: should they be used together? Curr Vasc Pharmacol. Nov 2010;8(6):742-746.

24.          Verdecchia P, Angeli F, Cavallini C, et al. The optimal blood pressure target for patients with coronary artery disease. Curr Cardiol Rep. Jul 2010;12(4):302-306.

25.          Reboldi G, Gentile G, Angeli F, Verdecchia P. Blood pressure lowering in the oldest old. J Hypertens. Jul 2010;28(7):1373-1376.

26.          Angeli F, Verdecchia P, Karthikeyan G, et al. Beta-blockers and risk of all-cause mortality in non-cardiac surgery. Ther Adv Cardiovasc Dis. Apr 2010;4(2):109-118.

27.          Angeli F, Verdecchia P, Karthikeyan G, Mazzotta G, Gentile G, Reboldi G. ss-Blockers reduce mortality in patients undergoing high-risk non-cardiac surgery. Am J Cardiovasc Drugs. 2010;10(4):247-259.

28.          Angeli F, Verdecchia P, Karthikeyan G, et al. New-onset hyperglycemia and acute coronary syndrome: a systematic overview and meta-analysis. Curr Diabetes Rev. Mar 2010;6(2):102-110.

29.          Angeli F, Reboldi G, Verdecchia P. Masked hypertension: evaluation, prognosis, and treatment. Am J Hypertens. Sep 2010;23(9):941-948.

30.          Angeli F, Reboldi G, Verdecchia P. "The lower the BP the better" paradigm in the elderly: vanished by VALISH? Hypertension. Aug 2010;56(2):182-184.

31.          Angeli F, Del Pinto M, Rasetti G, et al. [Management of ST-elevation myocardial infarction in the Umbria region: results from the observational prospective Umbria-STEMI registry]. G Ital Cardiol (Rome). May 2010;11(5):393-401.

32.          Angeli F, Angeli E, Cavallini C, et al. Electrocardiographic abnormalities of left ventricular repolarization: prognostic implications in hypertensive post-menopausal women. Maturitas. Oct 2010;67(2):159-165.

33.          Angeli F, Angeli E, Ambrosio G, Mazzotta G, Reboldi G, Verdecchia P. Neutrophil count for the identification of postmenopausal hypertensive women at increased cardiovascular risk. Obstet Gynecol. Apr 2010;115(4):695-703.

34.          Verdecchia P, Staessen JA, Angeli F, et al. Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial. Lancet. Aug 15 2009;374(9689):525-533.

35.          Verdecchia P, Angeli F, Repaci S, Mazzotta G, Gentile G, Reboldi G. Comparative assessment of angiotensin receptor blockers in different clinical settings. Vasc Health Risk Manag. 2009;5:939-948.

36.          Verdecchia P, Angeli F, Mazzotta G, Gentile G, Reboldi G. Home Blood Pressure Measurements Will Not Replace 24-Hour Ambulatory Blood Pressure Monitoring. Hypertension. Jul 6 2009.

37.          Verdecchia P, Angeli F, Mazzotta G, Gentile G, Reboldi G. Home Blood Pressure Measurements Will or Will Not Replace 24-Hour Ambulatory Blood Pressure Measurement. Hypertension. Sep 8 2009.

38.          Verdecchia P, Angeli F, Cavallini C, et al. The voltage of R wave in lead aVL improves risk stratification in hypertensive patients without ECG left ventricular hypertrophy. J Hypertens. Aug 2009;27(8):1697-1704.

39.          Verdecchia P, Angeli F, Cavallini C, et al. Blood pressure reduction and renin-angiotensin system inhibition for prevention of congestive heart failure: a meta-analysis. Eur Heart J. Mar 2009;30(6):679-688.

40.          Reboldi G, Gentile G, Angeli F, Verdecchia P. Choice of ACE inhibitor combinations in hypertensive patients with type 2 diabetes: update after recent clinical trials. Vasc Health Risk Manag. 2009;5(1):411-427.

41.          Reboldi G, Gentile G, Angeli F, Verdecchia P. Exploring the optimal combination therapy in hypertensive patients with diabetes mellitus. Expert Rev Cardiovasc Ther. Nov 2009;7(11):1349-1361.

42.          Angeli F, Verdecchia P, Del Pinto M, Cavallini C, Reboldi G. Perioperative beta blockade: the debate continues. Lancet. Feb 21 2009;373(9664):627; author reply 628.

43.          Angeli F, Reboldi G, Gentile G, Verdecchia P. The emerging role of high-density lipoprotein cholesterol in hypertension trials. J Hypertens. Mar 2009;27(3):458-460.

44.          Verdecchia P, Gentile G, Angeli F, Reboldi G. Should we prefer different drugs to treat hypertension in older and younger adults? Practical implications of clinical trials: European perspective. Pol Arch Med Wewn. Sep 2008;118(9):513-516.

45.          Verdecchia P, Angeli F, Sardone M, Borgioni C, Garofoli M, Reboldi G. Is the definition of daytime and nighttime blood pressure prognostically relevant? Blood Press Monit. Jun 2008;13(3):153-155.

46.          Verdecchia P, Angeli F, Reboldi G. Optimizing the definition of dippers and nondippers: is a 70-86% full glass empty? J Hypertens. Apr 2008;26(4):630-632.

47.          Verdecchia P, Angeli F, Mazzotta G, Gentile G, Reboldi G. The renin angiotensin system in the development of cardiovascular disease: role of aliskiren in risk reduction. Vasc Health Risk Manag. 2008;4(5):971-981.

48.          Verdecchia P, Angeli F, Borgioni C, et al. Prognostic value of circadian blood pressure changes in relation to differing measures of day and night. J Am Soc Hypertens. Mar-Apr 2008;2(2):88-96.

49.          Rolfo F, Bobbio M, Angeli F, Cavallini C. [The POISE study]. G Ital Cardiol (Rome). Dec 2008;9(12):803-807.

50.          Reboldi G, Angeli F, Cavallini C, Gentile G, Mancia G, Verdecchia P. Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis. J Hypertens. Jul 2008;26(7):1282-1289.

51.          Angeli F, Reboldi G, Repaci S, et al. [Ambulatory blood pressure monitoring in clinical practice]. G Ital Cardiol (Rome). Jun 2008;9(6):402-407.

52.          Angeli F, Gentile G, Reboldi G, Verdecchia P. Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and protection from stroke. Expert Rev Cardiovasc Ther. Oct 2008;6(9):1171-1174.

53.          Verdecchia P, Reboldi G, Angeli F, et al. Prognostic value of serial electrocardiographic voltage and repolarization changes in essential hypertension: the HEART Survey study. Am J Hypertens. Sep 2007;20(9):997-1004.

54.          Verdecchia P, Cavallini C, Angeli F, et al. [Antihypertensive therapy and cardiovascular prevention. The role of angiotensin II receptor blockers]. G Ital Cardiol (Rome). Aug 2007;8(8):491-497.

55.          Verdecchia P, Angeli F, Reboldi G. New-onset diabetes, antihypertensive treatment, and outcome. Hypertension. Sep 2007;50(3):459-460.

56.          Verdecchia P, Angeli F, Gattobigio R, Rapicetta C, Reboldi G. Impact of blood pressure variability on cardiac and cerebrovascular complications in hypertension. Am J Hypertens. Feb 2007;20(2):154-161.

57.          Verdecchia P, Angeli F, Gattobigio R, et al. The clinical significance of white-coat and masked hypertension. Blood Press Monit. Dec 2007;12(6):387-389.

58.          Verdecchia P, Angeli F, Cavallini C. Ambulatory blood pressure for cardiovascular risk stratification. Circulation. Apr 24 2007;115(16):2091-2093.

59.          Verdecchia P, Angeli F, Borgioni C, Gattobigio R, Reboldi G. Ambulatory blood pressure and cardiovascular outcome in relation to perceived sleep deprivation. Hypertension. Apr 2007;49(4):777-783.

60.          Verdecchia P, Angeli F, Achilli P, Castellani C, Repaci S, Ambrosio G. [Beta-blockers and arterial hypertension. Evidence-based medicine or excessive perseverance?]. G Ital Cardiol (Rome). Sep 2007;8(9):552-558.

61.          Verdecchia P, Angeli F, Achilli P, et al. Echocardiographic left ventricular hypertrophy in hypertension: marker for future events or mediator of events? Curr Opin Cardiol. Jul 2007;22(4):329-334.

62.          Verdecchia P, Angeli F. Does brachial pulse pressure predict coronary events? Adv Cardiol. 2007;44:150-159.

63.          de Simone G, Schillaci G, Chinali M, Angeli F, Reboldi GP, Verdecchia P. Estimate of white-coat effect and arterial stiffness. J Hypertens. Apr 2007;25(4):827-831.

64.          Verdecchia P, Angeli F, Taddei S. At the beginning of stiffening: endothelial dysfunction meets "pulsology". Hypertension. Oct 2006;48(4):541-542.

65.          Verdecchia P, Angeli F, Staessen JA. Compared with whom? Addressing the prognostic value of ambulatory blood pressure categories. Hypertension. May 2006;47(5):820-821.

66.          Verdecchia P, Angeli F, Reboldi G, Gattobigio R. Is the development of diabetes with antihypertensive therapy a problem?--Pro. J Clin Hypertens (Greenwich). Feb 2006;8(2):120-126.

67.          Verdecchia P, Angeli F, Gattobigio R, Sardone M, Pede S, Reboldi GP. Regression of left ventricular hypertrophy and prevention of stroke in hypertensive subjects. Am J Hypertens. May 2006;19(5):493-499.

68.          Verdecchia P, Angeli F, Gattobigio R, Angeli E, Pede S, Pittavini L. Validation of the A&D UA-705 device for self-measurement of blood pressure according to the British Hypertension Society protocol. Blood Press Monit. Aug 2006;11(4):223-227.

69.          Angeli F, Verdecchia P, Angeli E, et al. Day-to-day variability of electrocardiographic diagnosis of left ventricular hypertrophy in hypertensive patients. Influence of electrode placement. J Cardiovasc Med (Hagerstown). Nov 2006;7(11):812-816.

70.          Angeli F, Sardone M, Angeli E, Repaci S, Gattobigio R, Verdecchia P. Validation of the A&D wrist-cuff UB-511 (UB-512) device for self-measurement of blood pressure. Blood Press Monit. Dec 2006;11(6):349-354.

71.          Verdecchia P, Reboldi GP, Angeli F, et al. Short- and long-term incidence of stroke in white-coat hypertension. Hypertension. Feb 2005;45(2):203-208.

72.          Verdecchia P, Reboldi G, Angeli F, et al. Angiotensin-converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke prevention. Hypertension. Aug 2005;46(2):386-392.

73.          Verdecchia P, Angeli F, Reboldi GP, Gattobigio R. New-onset diabetes in treated hypertensive patients. Curr Hypertens Rep. Jun 2005;7(3):174-179.

74.          Verdecchia P, Angeli F, Gattobigio R, Sardone M, Porcellati C. Asymptomatic left ventricular systolic dysfunction in essential hypertension: prevalence, determinants, and prognostic value. Hypertension. Mar 2005;45(3):412-418.

75.          Verdecchia P, Angeli F, Gattobigio R, Reboldi GP. Do angiotensin II receptor blockers increase the risk of myocardial infarction? Eur Heart J. Nov 2005;26(22):2381-2386.

76.          Verdecchia P, Angeli F. Natural history of hypertension subtypes. Circulation. Mar 8 2005;111(9):1094-1096.

77.          Verdecchia P, Angeli F. The natural history of white-coat hypertension in the long term. Blood Press Monit. Apr 2005;10(2):65-66.

78.          Verdecchia P, Angeli F. How can we use the results of ambulatory blood pressure monitoring in clinical practice? Hypertension. Jul 2005;46(1):25-26.

79.          Reboldi G, Gentile G, Angeli F, Verdecchia P. Microalbuminuria and hypertension. Minerva Med. Aug 2005;96(4):261-275.

80.          Angeli F, Verdecchia P, Gattobigio R, Sardone M, Reboldi G. White-coat hypertension in adults. Blood Press Monit. Dec 2005;10(6):301-305.

81.          Verdecchia P, Reboldi G, Angeli F, et al. Prognostic value of lipoprotein fractions in essential hypertension. Blood Press. 2004;13(5):295-303.

82.          Verdecchia P, Reboldi G, Angeli F, et al. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension. May 2004;43(5):963-969.

83.          Verdecchia P, Angeli F, Poeta F, et al. Validation of the A&D UA-774 (UA-767Plus) device for self-measurement of blood pressure. Blood Press Monit. Aug 2004;9(4):225-229.

84.          Verdecchia P, Angeli F, Pittavini L, Gattobigio R, Benemio G, Porcellati C. Regression of left ventricular hypertrophy and cardiovascular risk changes in hypertensive patients. Ital Heart J. Jul 2004;5(7):505-510.

85.          Verdecchia P, Angeli F, Gattobigio R, Guerrieri M, Benemio G, Porcellati C. Does the reduction in systolic blood pressure alone explain the regression of left ventricular hypertrophy? J Hum Hypertens. Dec 2004;18 Suppl 2:S23-28.

86.          Verdecchia P, Angeli F, Gattobigio R. Clinical usefulness of ambulatory blood pressure monitoring. J Am Soc Nephrol. Jan 2004;15 Suppl 1:S30-33.

87.          Verdecchia P, Angeli F. Assessment of the optimal daily dose of valsartan in patients with hypertension, heart failure, or both. Clin Ther. Apr 2004;26(4):460-472.

88.          Verdecchia P, Angeli F. Reversal of left ventricular hypertrophy: what have recent trials taught us? Am J Cardiovasc Drugs. 2004;4(6):369-378.

89.          Angeli F, Verdecchia P, Reboldi GP, et al. Meta-Analysis of effectiveness or lack thereof of angiotensin-converting enzyme inhibitors for prevention of heart failure in patients with systemic hypertension. Am J Cardiol. Jan 15 2004;93(2):240-243.

90.          Angeli F, Verdecchia P, Reboldi GP, et al. Calcium channel blockade to prevent stroke in hypertension: a meta-analysis of 13 studies with 103,793 subjects. Am J Hypertens. Sep 2004;17(9):817-822.

91.          Verdecchia P, Sleight P, Avanzini F, et al. Hypertrophy at ECG and its regression during treatment survey (HEART survey). Rationale, design and baseline characteristics of patients. Ital Heart J. Jul 2003;4(7):479-483.

92.          Verdecchia P, Reboldi G, Gattobigio R, et al. Atrial fibrillation in hypertension: predictors and outcome. Hypertension. Feb 2003;41(2):218-223.

93.          Verdecchia P, Angeli F, Reboldi G, et al. Improved cardiovascular risk stratification by a simple ECG index in hypertension. Am J Hypertens. Aug 2003;16(8):646-652.

94.          Verdecchia P, Angeli F, Gattobigio R, Porcellati C. Ambulatory blood pressure monitoring and prognosis in the management of essential hypertension. Expert Rev Cardiovasc Ther. May 2003;1(1):79-89.

95.          Verdecchia P, Angeli F, Borgioni C, et al. Changes in cardiovascular risk by reduction of left ventricular mass in hypertension: a meta-analysis. Am J Hypertens. Nov 2003;16(11 Pt 1):895-899.

96.          Verdecchia P, Angeli F. [The Seventh Report of the Joint National Committee on the Prevention, Detection, Evaluation and Treatment of High Blood Pressure: the weapons are ready]. Rev Esp Cardiol. Sep 2003;56(9):843-847.

97.          Pasqualini L, Marchesi S, Vaudo G, et al. Association between endothelial dysfunction and major cardiovascular events in peripheral arterial disease. Vasa. Aug 2003;32(3):139-143.

98.          Bagliani G, Michelucci A, Angeli F, Meniconi L. Atrial activation analysis by surface P wave and multipolar esophageal recording after cardioversion of persistent atrial fibrillation. Pacing Clin Electrophysiol. May 2003;26(5):1178-1188.

99.          Angeli F, Verdecchia P, Pellegrino C, et al. Association between periodontal disease and left ventricle mass in essential hypertension. Hypertension. Mar 2003;41(3):488-492.

100.        Verdecchia P, Reboldi G, Porcellati C, et al. Risk of cardiovascular disease in relation to achieved office and ambulatory blood pressure control in treated hypertensive subjects. J Am Coll Cardiol. Mar 6 2002;39(5):878-885.